A5001125407- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiovascular Issues in Pregnancy
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Cardiac Arrhythmias and Treatments
- Cardiac Health and Mental Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Pregnancy and preeclampsia studies
- Atrial Fibrillation Management and Outcomes
- Cardiomyopathy and Myosin Studies
- Respiratory Support and Mechanisms
- Cardiac Valve Diseases and Treatments
- Cardiac Arrest and Resuscitation
- Pericarditis and Cardiac Tamponade
- Cardiac tumors and thrombi
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Effects of Exercise
- Cardiac electrophysiology and arrhythmias
- Mechanical Circulatory Support Devices
- Coronary Artery Anomalies
- Protein Interaction Studies and Fluorescence Analysis
Cytokinetics (United States)
2022-2025
Oregon Health & Science University
2020-2023
Clinical Research Institute
2023
Duke University
2023
San Francisco VA Medical Center
2017-2022
British Heart Foundation
2022
University of Glasgow
2022
University of California, San Francisco
2017-2022
Yale University
2022
The University of Texas Southwestern Medical Center
2011-2016
<h3>Importance</h3> Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but not consistently improved by any the current guideline-directed medical therapies. <h3>Objective</h3> To determine whether omecamtiv mecarbil, novel direct myosin activator that improves cardiac performance and reduces risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity patients chronic HFrEF. <h3>Design, Setting,...
Background Cardiovascular complications of pregnancy present an opportunity to assess risk for subsequent cardiovascular disease. We sought determine whether peripartum cardiomyopathy and hypertensive disorder subtypes predict future myocardial infarction, heart failure or stroke independent one another other risks such as gestational diabetes, preterm birth intrauterine growth restriction. Methods results The California Healthcare Cost Utilization Project database was used identify all...
A 48-year-old woman with a past medical history of migraines and hyperlipidemia presented due to severe retrosternal chest pain no other associated signs or symptoms. The patient was hemodynamically stable found have an elevated troponin electrocardiogram showing ischemic changes. Computed tomography the coronary arteries showed left dominant system dissection extending from mid-to-distal anterior descending (LAD) artery. subsequently discharged on therapy but returned 3 days later worsening...
Abstract Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose this study was to determine absorption, metabolism, and excretion aficamten. Eight healthy male participants received single oral dose 20 mg aficamten (containing approximately 100 μCi radiocarbon). Blood, urine, feces samples were collected up maximum Day 26. pharmacokinetics characterized by moderate median t max 2.0 h postdose....
Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated these in US practice is well described. Methods Results We examined hospitalized worsening chronic ≤40% from 2014 to 2019 the GWTG-HF (Get With Guidelines-Heart Failure) registry, who did receive HF or end-stage kidney disease. Patients EF defined as ≤30% were compared...
In the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial, omecamtiv mecarbil, compared with placebo, reduced risk of worsening heart failure (HF) events, or cardiovascular death patients HF and ejection fraction. The primary aim this prespecified analysis was evaluate safety efficacy mecarbil by randomization setting, that is, whether participants were enrolled as outpatients inpatients.
There is a paucity of data on cardiogenic shock (CS) incidence and outcomes among patients with spontaneous coronary artery dissection (SCAD).Women admitted to the hospital for acute myocardial infarction (AMI) without SCAD were identified from United States National Readmission Database October 1, 2015 December 31, 2018. We calculated CS women AMI odds developing after adjusting baseline characteristics. In addition, we report utilization percutaneous intervention, mechanical circulatory...
Introduction: Characterized by significant left ventricular (LV) dysfunction and clinical heart failure (HF), peripartum cardiomyopathy (PPCM) has an incidence of approximately 1/2200 live births (0.04%). Prior studies estimate that 25% those with recovered LV function will have recurrent PPCM during subsequent pregnancies, compared to 50% without function. Specific predictors not been studied in cohorts large numbers. Methods: From 2005-2011, we identified 1,872,227 pregnancies...
More than 60 years after the first description of “asymmetric septal hypertrophy heart,” hypertrophic cardiomyopathy (HCM) as a disease has continued to provide clinicians and researchers fertile grounds for debate investigation. HCM, complex requiring multidisciplinary approach, runs gamut all we learned in medical school beyond – physiology, clinical medicine, genetics, imaging, diagnostics, pharmacotherapies, electrophysiology, interventional cardiology, cardiothoracic surgical...
Background: An estimated two-thirds of heart failure (HF) patients with reduced ejection fraction (HFrEF) hospitalized in the United States have a severely left ventricular (LVEF <30%). Few studies categorized according to their severity dysfunction beyond an LVEF <30%.Methods: Intermountain Health (≥18 years), primary HF diagnosis, ≥1 inpatient hospitalization discharge diagnosis HF, documented <30%, and BNP >100 pg/mL within one year were studied. Patients stratified by levels (≤15%,...